Aging & Elder Health Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Aging & Elder Health Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
GlaxoSmithKline, PLC
Relafen suit settled
January 9th, 2005
United States District Court Judge William G. Young granted preliminary approval of a proposed settlement between GlaxoSmithKline, PLC, SmithKline Beecham Corp., Beecham Group, PLC, and SmithKline Beecham, PLC, and a class of consumers and third-party payors who purchased the prescription drug Relafen, reported the plaintiff's attorney's. The suit, comprised of many federal cases consolidated in United States District Court in Massachusetts, alleged that Relafen's distributors unlawfully obtained a patent which allowed them to enforce a monopoly over Relafen and prevent competition by generic prescription drugs. The suit contended that this conduct resulted in consumers...
Source: Aging & Elder Health Week (2005-01-09)
|
